Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
PRINCETON, N.J., Oct. 02, 2017 -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City.
Members of Agile’s executive team will review clinical data and discuss the commercialization plan for Twirla®, the company's lead investigational once weekly low-dose prescription contraceptive patch. Management will be joined by leading external experts who will provide clinical perspectives on Twirla, as well as regulatory and market access insights into today’s contraceptive marketplace.
To access the live webcast, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. A replay will be available on the company’s website.
| Event Details | |
| Date: | Tuesday, October 10, 2017 |
| Time: | 11:00 a.m. – 1:30 p.m. ET |
| Location: | New York City |
| Speakers will include: | |
| Alfred Altomari | Chairman and CEO, Agile Therapeutics |
| Elizabeth Garner, M.D., MPH | Senior Vice President, Chief Medical Officer, Agile Therapeutics |
| Renee Selman | Chief Commercial Officer, Agile Therapeutics |
| Robin Kroll, M.D., FACOG | Director, Seattle Women’s: Health, Research, Gynecology; |
| SECURE Trial Investigator | |
| David J. Portman, M.D., FACOG | Director Emeritus, Columbus Center for Women’s Health |
| Research; CEO and Chief Medical Officer, Sermonix | |
| Pharmaceuticals | |
| Minnie Baylor-Henry, J.D., R.Ph | Executive Partner, YourEncore; Former Director, Division of |
| Drug Marketing, Advertising and Communications (DDMAC), | |
| Food and Drug Administration; Former Worldwide Vice | |
| President, Regulatory Affairs, Johnson & Johnson | |
| Adaeze Enekwechi, PhD, MPP | VP, McDermottPlus Consulting in Washington,D.C.; Former |
| Associate Director for Health Programs, White House Office of | |
| Management and Budget under President Obama | |
Analysts and institutional investors seeking more information about this event should contact Matt Ventimigila by phone or email: [email protected], or 212-599-1265.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.
Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.
About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.
Contact:
Mary Coleman
Agile Therapeutics, Inc.
609-356-1921
